HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

By BioPharma Dive · Apr 15, 2026 · via BioPharma Dive
Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
dealsformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Lilly Spends Up to $3.8B on Three Vaccine Developers
DealsBriefing
Lilly Spends Up to $3.8B on Three Vaccine Developers
The pharma giant’s latest acquisitions of Curevo, LimmaTech, and Vaccine Company reinforce its pivot from trea…
May 26, 2026
Medtronic inks $650M deal for SPR Therapeutics
DealsFierceBiotech ↗
Medtronic inks $650M deal for SPR Therapeutics
Medtronic has entered a deal to acquire SPR Therapeutics, a Cleveland-based company whose flagship product del…
May 24, 2026
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
DealsPharmaceutical Technology ↗
CVC consortium tables $12.4bn bid to delist Italian drugmaker Recordati
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
May 22, 2026